<DOC>
	<DOCNO>NCT01461967</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , cross-over study ass safety , pharmacokinetics pharmacodynamics RO5508887 healthy volunteer . In Part 1 , subject randomize receive single ascending dos either RO5508887 placebo . In Part 2 , subject receive single dose RO5508887 two occasion , without food . Anticipated time study 12 week .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics Pharmacodynamics RO5508887 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer , 1845 ( Part 1 ) 1865 ( Part 2 ) year age inclusive ; healthy status define absence evidence active chronic disease Body Mass Index ( BMI ) 18 30 kg/m2 inclusive Male subject must use barrier method contraception duration study 30 day last dose Suspicion regular consumption drug abuse Regular smoker ( &gt; 5 cigarette , &gt; 1 pipeful &gt; 1 cigar per day ) Positive hepatitis B , hepatitis C HIV infection History hypersensitivity severe drug reaction Participation investigational drug device study within three month first drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>